These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1580 related items for PubMed ID: 19669644

  • 1. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A, O'Brien M, Sommer H, Nowara E, Welt A, Pienkowski T, Rolski J, Pham ML, Perraud K, Trillet-Lenoir V.
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [Abstract] [Full Text] [Related]

  • 2. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
    Campone M, Isambert N, Bourbouloux E, Roché H, Bonneterre J, Milano G, Fumoleau P.
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer.
    Nolè F, Crivellari D, Mattioli R, Pinotti G, Foa P, Verri E, Fougeray R, Brandely M, Goldhirsch A.
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):673-80. PubMed ID: 19184601
    [Abstract] [Full Text] [Related]

  • 4. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Fan Y, Xu B, Yuan P, Wang J, Ma F, Li Q, Zhang P, Li Q, Cai R.
    Chemotherapy; 2010 Sep; 56(4):340-7. PubMed ID: 20720418
    [Abstract] [Full Text] [Related]

  • 5. A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Estévez LG, Batista N, Sánchez-Rovira P, Velasco A, Provencio M, León A, Dómine M, Cruz J, Rodríguez M.
    Clin Breast Cancer; 2008 Apr; 8(2):149-54. PubMed ID: 18621611
    [Abstract] [Full Text] [Related]

  • 6. A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines.
    Campone M, Dobrovolskaya N, Tjulandin S, Chen SC, Fourie S, Mefti F, Konstantinova M, Lefresne F, Meheust N, Jassem J.
    Breast J; 2013 Apr; 19(3):240-9. PubMed ID: 23528159
    [Abstract] [Full Text] [Related]

  • 7. All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer.
    Tawfik H, Rostom Y, Elghazaly H.
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):913-9. PubMed ID: 23344713
    [Abstract] [Full Text] [Related]

  • 8. A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer.
    Finek J, Holubec L, Svoboda T, Sefrhansova L, Pavlikova I, Votavova M, Sediva M, Filip S, Kozevnikova R, Kormunda S.
    Anticancer Res; 2009 Feb; 29(2):667-70. PubMed ID: 19331218
    [Abstract] [Full Text] [Related]

  • 9. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
    Zhang J, Gu SY, Gan Y, Wang ZH, Wang BY, Guo HY, Wang JL, Wang LP, Zhao XM, Hu XC.
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):103-13. PubMed ID: 23053266
    [Abstract] [Full Text] [Related]

  • 10. Second-line combination chemotherapy with vinorelbine and capecitabine in patients with advanced breast cancer previously treated with anthracyclines and/or taxanes.
    Mao W, Guan X, Tucker S, Li F, He Z, Wang J, Guo J, Wu S.
    Chemotherapy; 2011 Jan; 57(1):71-6. PubMed ID: 21293121
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
    Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Lerzo GL, Pivot XB, Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roché HH.
    Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
    [Abstract] [Full Text] [Related]

  • 17. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
    Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Rudas M, Mader RM, Gnant M, Zielinski CC, Steger GG.
    J Clin Oncol; 2007 Sep 01; 25(25):3853-8. PubMed ID: 17679724
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
    Schaller G, Fuchs I, Gonsch T, Weber J, Kleine-Tebbe A, Klare P, Hindenburg HJ, Lakner V, Hinke A, Bangemann N.
    J Clin Oncol; 2007 Aug 01; 25(22):3246-50. PubMed ID: 17577021
    [Abstract] [Full Text] [Related]

  • 19. Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies.
    Jassem J, Fein L, Karwal M, Campone M, Peck R, Poulart V, Vahdat L.
    Breast; 2012 Feb 01; 21(1):89-94. PubMed ID: 21937232
    [Abstract] [Full Text] [Related]

  • 20. Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy.
    Palomo AG, Glogowska I, Sommer H, Malamos N, Kilar E, Vega JM, Torrecillas L, Delozier T, Ettl J, Finek J.
    Anticancer Res; 2012 Oct 01; 32(10):4539-45. PubMed ID: 23060583
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 79.